These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 26390769)

  • 21. Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction.
    Resnick RB
    Ann Intern Med; 2003 Feb; 138(4):360. PubMed ID: 12585846
    [No Abstract]   [Full Text] [Related]  

  • 22. Office-based practice and opioid-use disorders.
    Clark HW
    N Engl J Med; 2003 Sep; 349(10):928-30. PubMed ID: 12954740
    [No Abstract]   [Full Text] [Related]  

  • 23. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
    Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
    Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The implementation of buprenorphine/naloxone in college health practice.
    DeMaria PA; Patkar AA
    J Am Coll Health; 2008; 56(4):391-3. PubMed ID: 18316282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.
    Barbosa-Leiker C; McPherson S; Layton ME; Burduli E; Roll JM; Ling W
    Am J Drug Alcohol Abuse; 2018; 44(4):488-496. PubMed ID: 29672167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
    Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA
    Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals.
    Amass L; Pukeleviciene V; Subata E; Almeida AR; Pieri MC; D'Egidio P; Stankova Z; Costa A; Smyth BP; Sakoman S; Wei Y; Strang J
    Addiction; 2012 Jan; 107(1):142-51. PubMed ID: 21749526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
    McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
    J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of opioid painkiller dependence in primary care: ongoing recovery with buprenorphine/naloxone.
    Hard B
    BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25432908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugs approved for opiate dependence.
    FDA Consum; 2003; 37(1):6. PubMed ID: 12625293
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy.
    Parran TV; Adelman CA; Merkin B; Pagano ME; Defranco R; Ionescu RA; Mace AG
    Drug Alcohol Depend; 2010 Jan; 106(1):56-60. PubMed ID: 19717249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.
    Renzelli CM; Capretto NA
    J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial.
    D'Onofrio G; O'Connor PG; Pantalon MV; Chawarski MC; Busch SH; Owens PH; Bernstein SL; Fiellin DA
    JAMA; 2015 Apr; 313(16):1636-44. PubMed ID: 25919527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of characteristics and outcomes of opioid-dependent patients initiating office-based buprenorphine or methadone maintenance treatment.
    Fingerhood MI; King VL; Brooner RK; Rastegar DA
    Subst Abus; 2014; 35(2):122-6. PubMed ID: 24821346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Buprenorphine maintenance: a new treatment for opioid dependence.
    Collins GB; McAllister MS
    Cleve Clin J Med; 2007 Jul; 74(7):514-20. PubMed ID: 17682629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Narrative review: buprenorphine for opioid-dependent patients in office practice.
    Sullivan LE; Fiellin DA
    Ann Intern Med; 2008 May; 148(9):662-70. PubMed ID: 18458279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Is the availability of buprenorphine/naloxone therapy for opioid-dependent inmates a necessity? ].
    Marco A; López-Burgos A; García-Marcos L; Gallego C; Antón JJ; Errasti A
    Rev Esp Sanid Penit; 2013 Feb; 15(3):105-13. PubMed ID: 24270319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.
    Leshner AI
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S103-4. PubMed ID: 12738354
    [No Abstract]   [Full Text] [Related]  

  • 39. [Changes in psychosocial symptoms of opiate users over six months with buprenorphine/naloxone substitution therapy].
    Petke Z; Csorba J; Meszaros J; Vingender I; Farkas J; Demetrovics Z; Kovacs Z; Menczel Z; Pataki Z; Simor P; Havasi A; Melles K; Marvanykovi F; Racz J
    Neuropsychopharmacol Hung; 2012 Mar; 14(1):7-17. PubMed ID: 22427466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.